MIM
PASG icon

MetLife Investment Management’s Passage Bio PASG Stock Holding History

MetLife Investment Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-537
Closed -$68.1K – 2758
2021
Q4 		$68.1K Hold
537
– – ﹤0.01% 2461
2021
Q3 		$107K Hold
537
– – ﹤0.01% 2419
2021
Q2 		$142K Hold
537
– – ﹤0.01% 2345
2021
Q1 		$188K Hold
537
– – ﹤0.01% 2094
2020
Q4 		$274K Buy
537
+196
+57% +$78.5K ﹤0.01% 1813
2020
Q3 		$89.3K Hold
341
– – ﹤0.01% 2234
2020
Q2 		$186K Buy
+341
New +$153K ﹤0.01% 1952

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

MetLife Investment Management's PASG Position: Q1 2022 in Review

MetLife Investment Management sold out of Passage Bio (PASG) in Q1 2022, closing a stake of 537 shares — an estimated $68.1K sold.

MetLife Investment Management first reported a position in PASG in Q2 2020 and held it in 7 quarters. The position peaked at $274K in Q4 2020. 108 funds tracked by Wall St. Rank hold PASG as of Q1 2022.

  • MetLife Investment Management reported no remaining Passage Bio position as of Q1 2022 after selling out during the quarter.
  • MetLife Investment Management sold 537 Passage Bio shares in Q1 2022, an estimated $68.1K.
  • MetLife Investment Management first reported a position in Passage Bio in Q2 2020 and held it in 7 quarters.
  • MetLife Investment Management's Passage Bio position peaked at $274K in Q4 2020.
  • 108 funds tracked by Wall St. Rank held Passage Bio as of Q1 2022.

Based on MetLife Investment Management's 13F filing for Q1 2022, filed 12 May 2022.